RankAlpha logo
Back to Rankings

MDCX

MedicusF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The best verified post-earnings bull argument is that SkinJect data quality improved after the May 6 expanded analysis, while the May 14 update kept both SkinJect and Teverelix moving through regulatory and protocol milestones; for a $16.6 million micro-cap, any credible FDA-path de-risking can matter disproportionately.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Coverage is thin and I did not verify meaningful post-earnings analyst revision support, so the setup remains monitoring-oriented rather than fully confirmed.
Momentum
11
Value
46
Sentiment
19
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.22 · Bull $0.60 · Bear $0.10
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $5.67
Why
Momentum11 · Δ7d -
Value46 · Δ7d +0.0
Sentiment19 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
11
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
19
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 10.9 / Value 46.4 / Sentiment 19.4

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$20.06M
Beta
-
Shares Out
22.03M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.96
Rev YoY
-
EPS YoY
-23.2%
Gross Margin
-
Op Margin
-
Net Debt
-$2.36M
Current Ratio
1.22
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology